eISSN 2329-0358

Logo



Get your full text copy in PDF

Treosulfan, Cyclophosphamide and Antithymocyte Globulin for Allogeneic Hematopoietic Cell Transplantation in Acquired Severe Aplastic Anemia

Sebastian Giebel, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Miroslaw Markiewicz, Iwona Wylezol, Marek Seweryn, Aleksandra Holowiecka-Goral, Jerzy Holowiecki

Ann Transplant 2006; 11(2): 23-27

ID: 496979


To reduce the risk of graft rejection after allogeneic hematopoietic cell transplantation (alloHCT) for patients with acquired severe aplastic anemia (SAA), we introduced an intensified preparative regimen consisting of treosulfan 10g/m2/d on days -7, -6, cyclophosphamide 40 mg/kg/d on days -5, -4, -3, -2 and anti-thymocyte globulin 2 mg/kg/d on days -3, -2, -1. Six patients with the history of multiple transfusions were treated with alloHCT from either HLA-identical sibling (n=3) or an unrelated volunteer (n=3). Each, bone marrow and peripheral blood was used as a source of stem cells in three cases. All patients engrafted and achieved complete donor chimerism. None of the patients experienced severe organ toxicity. No severe acute graftversus- host-disease (GVHD) was observed; two patients experienced extensive chronic GVHD. At the median follow-up of 14.5 (13-27) months all patients remained alive and disease-free. Our observation indicates that treosulfan + cyclophosphamide + antithymocyte globulin conditioning is well-tolerated and allows stable engraftment in acquired SAA.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree